TB KaSPar
Feedback
Infants aged under 3 months or weighing less than 3 kg (including premature birth (under 37 weeks) were not eligible for inclusion in the SHINE trial. No new data on treatment of congenital TB and very young infants aged 0–3 months with TB disease were received following a call for data.
As in adults, TB treatment in children and adolescents includes a 2-month intensive phase followed by a continuation phase of 2–4 months. In the intensive phase, TB bacilli are rapidly killed to prevent disease progression, transmission and development of drug resistance. In the continuation phase, dormant bacilli are eliminated to effect cure and prevent relapse.
Any child aged under 10 years who has had close contact with a person with TB disease should be screened for TB with a symptom screen or CXR as part of contact investigation. Symptoms used to screen for TB are cough for more than 2 weeks, fever for more than 2 weeks, and poor weight gain or weight loss in the past 3 months. In young children, reduced playfulness or lethargy should also be included, since prolonged cough may be absent in children with disseminated disease.
Screening serves to identify children and adolescents who may have TB disease (presumptive TB) and who need further evaluation to make or confirm a TB diagnosis (see Chapter 4). It also helps to identify children and adolescents who are eligible for and could benefit from TPT. A screening test is not intended to be a diagnostic tool. People with positive results on a screening test should undergo further diagnostic evaluation.
By reducing cell-mediated immunity, undernutrition increases the risk of TB, while the catabolic effect of TB disease results in weight loss and wasting, creating a vicious cycle (105, 228). Globally, about 45% of deaths in children aged under 5 years are attributable to undernutrition (228). Undernutrition may be acute or chronic and categorized as moderate or severe.
TB disease should be excluded in neonates born to women with presumptive or confirmed TB. The level of infectiousness and drug susceptibility in the mother should be determined. It is not necessary to separate the neonate from the mother. Breastfeeding should be continued and the mother advised to wear a surgical mask when close to the baby (191).
In general, TB medicines should be dosed according to body weight. Dosing of bedaquiline and delamanid for children and young adolescents aged under 15 years was updated in 2021 following an expert consultation meeting convened by WHO. These dosing recommendations are included in Annex 6 and may be updated as evidence emerges, especially for the youngest age groups, for which there is very limited evidence.
Based on modelling estimates, between 25 000 and 32 000 children and young adolescents aged under 15 years develop MDR-TB disease annually (110). When treated, outcomes of children with MDR/RR-TB are good, with favourable outcomes in 78% (111) and over 90% in some cohorts (112). Despite these good outcomes, relatively few children are diagnosed and treated for MDR/RR-TB each year, with only 12 220 starting treatment between 2018 and 2020 (11% of the United Nations General Assembly High-level Meeting target of 115 000) (1, 9).
About a quarter of the world’s population has been infected with Mycobacterium tuberculosis. The vast majority of these people do not have TB disease (10). It is estimated that 7.5 million children and young adolescents aged under 15 years are newly infected with M. tuberculosis each year (11). Cumulatively, about 67 million children and young adolescents aged under 15 years are infected with M.
TB is a common cause or comorbidity in children with clinically diagnosed pneumonia. A systematic review on TB in acute respiratory infection found that M. tuberculosis was identified in around 5–10% of children with pneumonia aged under 5 years in TB endemic countries (223). Limited data from clinical and autopsy studies suggest that TB was also associated with mortality in these children. Prevalence studies, including the multisite PERCH study (224), confirm these findings.